Loading clinical trials...
Loading clinical trials...
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT00742144 · Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
NCT01077622 · Leukaemia, Lymphocytic, Chronic
NCT01563055 · Leukaemia, Lymphocytic, Chronic
Novartis Investigative Site
Boca Raton, Florida
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Clinton, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions